Mazal plans to use common stock to secure large-scale cholesterol drug trial sites

By Lisa Kerner

Charlotte, N.C., Aug. 8 - Mazal Plant Pharmaceuticals Inc. said it is negotiating with several clinical sites to conduct its Food and Drug Administration-approved study of the HDL-elevating drug, Mahdl.

The company plans to use its common stock as partial payment for the study in order to conserve working capital for other corporate requirements, according to a news release.

Mazal will conduct a large-scale double-blind, four-arm study in human subjects diagnosed with alphalipoproteinemia (subjects with low HDL). Study subjects will be given either Mahdl, placebo, statin and placebo or Mahdl and statin for four months.

The study will measure changes in HDL, LDL, cholesterol, triglycerides and CRP serum levels, the company said..

Mazal is an early-stage whole plant pharmaceutical development company located in New York City.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.